Changes in energy metabolism in pheochromocytoma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1651-1658

  Petrak O ^a   Haluzikova D ^a   Kavalkova P ^a   Strauch B ^a   Rosa, J ^a   Holaj, R ^a   Vránková, A Brabcová ^a   Michalsky, D ^a   Haluzik M ^a   Zelinka, T ^a   Widimsky, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C REACTIVE PROTEIN; CATECHOLAMINE; GLUCOSE; INTERLEUKIN 6; INTERLEUKIN 8; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ADRENALIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD ANALYSIS EQUIPMENT; BODY FAT; BODY MASS; BODY SURFACE; CALORIMETRY; CATECHOLAMINE SYNTHESIS; CLINICAL ARTICLE; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERMETABOLISM; INFLAMMATION; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PHEOCHROMOCYTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 84876214519     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3625     Document Type: Article

References (40)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacák K. Phaeochromocytoma. Lancet. 2005; 366: 665-675.
2. Zelinka T, Eisenhofer G, Pacák K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress (Amsterdam, Netherlands). 2007; 10: 195-203.
3. Holaj R, Zelinka T, Wichterle D, et al. Increased carotid intimamedia thickness in patients with pheochromocytoma in comparison to essential hypertension. J Hum Hypertens. 2009; 23: 350-358.
4. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009; 89: 381-410.
5. Mráz M, Lacinová Z, Drápalová J, et al. The effect of very-lowcalorie diet on mRNA expression of inflammation-related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2011; 96: E606-E613.
6. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996; 51: 819-824.
7. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-743.
8. Moorhead EL 2nd, Caldwell JR, Kelly AR, Morales AR. The diagnosis of pheochromocytoma. Analysis of 26 cases. JAMA. 1966; 196: 1107-1113.
9. McCullagh EP, Engel WJ. Pheochromocytoma with hypermetabolism: report of two cases. Ann Surg. 1942; 116: 61-75.
10. Sato T, Yoshinaga K, Oikawa A, Torikai T. Pheochromocytoma in Japan. Jap Heart J. 1966; 7: 419-429.
11. Gifford RW Jr, Kvale WF, Maher FT, Roth GM, Priestley JT. Clinical features, diagnosis and treatment of pheochromocytoma: a review of 76 cases. Mayo Clin Proc. 1964; 39: 281-302.
12. Cooper JA, Watras AC, O'Brien MJ, et al. Assessing validity and reliability of resting metabolic rate in six gas analysis systems. J Am Diet Assoc. 2009; 109: 128-132.
13. Harris JA, Benedict FG A biometric study of human basal metabolism. Proc Natl Acad Sci USA. 1918; 4: 370-373.
14. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med. 2007; 35: S508-S518.
15. Matthews DE, Pesola G, Campbell RG. Effect of epinephrine on amino acid and energy metabolism in humans. Am J Physiol. 1990; 258: E948-E956.
16. Bessey PQ, Watters JM, Aoki TT, Wilmore DW. Combined hormonal infusion simulates the metabolic response to injury. Ann Surg. 1984; 200: 264-281.
17. Ratheiser KM, Brillon DJ, Campbell RG, Matthews DE. Epinephrine produces a prolonged elevation in metabolic rate in humans. Am J Clin Nutr. 1998; 68: 1046-1052.
18. Wolfe RR, Shaw JH. Effect of epinephrine infusion and adrenergic blockade on glucose oxidation in conscious dogs. Metab Clin Expl. 1986; 35: 673-678.
19. Ensinger H, Weichel T, Lindner KH, Grunert A, Ahnefeld FW. Effects of norepinephrine, epinephrine, and dopamine infusions on oxygen consumption in volunteers. Crit Care Med. 1993; 21: 1502-1508.
20. Watt MJ, Howlett KF, Febbraio MA, Spriet LL, Hargreaves M. Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. J Physiol. 2001; 534: 269-278.
21. Hoeks J, van Baak MA, Hesselink MK, et al. Effect of β1- and β2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab. 2003; 285: E775-E782.
22. Jones CT, Ritchie JW. The metabolic and endocrine effects of circulating catecholamines in fetal sheep. J Physiol. 1978; 285: 395-408.
23. Cases A, Bono M, Gaya J, et al. Reversible decrease of surface β2-adrenoceptor number and response in lymphocytes of patients with pheochromocytoma. Clin Exp Hypertens. 1995; 17: 537-549.
24. Henry CJ. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr. 2005; 8: 1133-1152.
25. Gazzola C. a2-Adrenoceptor-mediated effects on resting energy expenditure. Int J Obes Relat Metab Disord. 1993; 17: 637-641.
26. Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging. 2010; 2: 361-368.
27. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008; 9: 20-29.
28. Delano MJ, Moldawer LL. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract. 2006; 21: 68-81.
29. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004; 90: 464-470.
30. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science (New York), NY. 2000; 289: 2363-2366.
31. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996; 335: 1897-1905.
32. Zelinka T, Petrák O, Strauch B, et al. Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. Neuroimmunomodulation. 2007; 14: 57-64.
33. Bosanská L, Petrák O, Zelinka T, Mráz M, Widimsky J Jr, Haluzík M. The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue. Physiol Res. 2009; 58: 319-325.
34. Petrák O, Strauch B, Zelinka T, et al. 2010 Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertens Res. 33: 454-459.
35. Price SR, Olivecrona T, Pekala PH. Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor-the primary regulatory role of the hormone in 3T3-L1 adipocytes. Arch Biochem Biophys. 1986; 251: 738-746.
36. Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, Arner P. Targets for TNF-a-induced lipolysis in human adipocytes. Biochem Biophys Res Commun. 2004; 318: 168-175.
37. Goryo K, Torii S, Yasumoto K, Sogawa K. Tumour necrosis factor-a suppresses the hypoxic response by NF-κB-dependent induction of inhibitory PAS domain protein in PC12 cells. J Biochem. 2011; 150: 311-318.
38. Tong AL, Zeng ZP, Li HZ, Yang D, Lu L, Li M. Expression and effect of transforming growth factor-a and tumor necrosis factor-a in human pheochromocytoma. Ann NY Acad Sci. 2006; 1073: 277-283.
39. Maltoni M, Fabbri L, Nanni O, et al. Serum levels of tumour necrosis factor a and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer. 1997; 5: 130-135.
40. Derosa G, Cicero AF, D'Angelo A, et al. Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. J Cardiovasc Pharmacol. 2006; 47: 508-512.